Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Neurofibromatosis 1 7Neurofibroma, Plexiform 4Neoplasms 2Melanoma 2Lung Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Breast Neoplasms 2Pancreatic Neoplasms 1Pain 1Neurofibrosarcoma 1Kidney Neoplasms 1Colonic Neoplasms 1Carcinoma, Squamous Cell 1Astrocytoma 1Advanced Non Small Cell Lung Cancer 1Adenocarcinoma 1

Interventions

Oxaliplatin 9Capecitabine 9Fluorouracil 7pembrolizumab 6Paclitaxel 6Leucovorin 6Cisplatin 5zolbetuximab 4trastuzumab deruxtecan 3enzalutamide 3durvalumab 3cemiplimab 3Trastuzumab 3Gemcitabine 3Docetaxel 3fludarabine 2darolutamide 2Taxes 2Ramucirumab 2Radiotherapy, Image-Guided 2Radiosurgery 2Pemetrexed 2Nivolumab 2Irinotecan 2Cyclophosphamide 2Carboplatin 2Albumin-Bound Paclitaxel 2130-nm albumin-bound paclitaxel 2vistusertib 1tucatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Adenocarcinoma × AZD 6244 × 90 days × Clear all
NCT02664935 2026-04-28

National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer

University of Birmingham

Phase 2 Completed
423 enrolled
Thoracic

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡